The Kenox Team is a group of highly motivated professionals committed to bringing superior drug products to patients around the world. Empowered by experience working with drug formulation and delivery, together with our industry savvy, we are fully equipped to deliver results and achieve goals in all our projects and initiatives.
Dr. Velaga is a highly accomplished and internationally recognized pharmaceutical professional with over 18 years of academic and industrial experience in the areas of solid-state chemistry, solubilization technologies, particle engineering, and the development of specialized dosage forms, including oral films and aerosol-based drug products. Dr. Velaga has proven himself a strong leader, having successfully built and led teams of highly skilled and motivated scientists and scholars. He has established strong business and professional relationships with pioneering scientists, universities, and pharmaceutical companies in a number of countries around the world. He brings his years of experience in drug-product development, innovative research, project management, business development, and strategy to Kenox.
Robert is a demonstrated C-level and senior leadership experience in public, private, revenue stage and development stage companies and have played a leading role in 2 start-ups. Experienced in all stages of the business lifecycle with specific knowledge of life sciences and medical device companies and how to articulate complex and/or scientific concepts to a business audience. Expertise in public and private financings, M&A, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as building organizations and interacting with Boards, VC’s, shareholders and Wall Street. Prior career as an investment banker, mostly at Lehman Brothers, with deal experience split between M&A and capital markets transactions in a variety of industries, including consumer goods, energy and high technology. MBA from The Wharton School and an AB from Princeton University.
Mr. Stadermann is a Chemical Engineer and aerosol-based product-development scientist with over 12 years of experience in the development and manufacturing of pMDIs and DPIs. He has strong technical expertise in the development, submission, and patent litigations of inhalation drug substances and drug products. He has a proven track record in both generic and innovative development at a number of prestigious pharmaceutical companies, including Teva, Solvay, and Merck. Mr. Stadermann has authored CMC sections for various clinical and commercial inhalation products, and has directly engaged with global regulatory authorities (EMEA, US, JP, LATAM, and RoW). Among his key achievements are the successful development and approval of budesonide/formoterol and fluticasone/salmeterol products.
Dr. Igor Gonda is the founder of Respidex LLC – a consulting firm assisting pharmaceutical companies in corporate strategy, including R&D program design, collaborations with patient advocacy groups, regulatory process, intellectual property management, financing and business development. He was previously CEO of the inhalation company Aradigm Corp and transdermal delivery company Acrux Ltd. Prior to that, he conducted aerosol research and product development at Genentech Inc. (USA) and at universities in the UK, USA and Australia. He has over 120 US patents and patent applications and published over a hundred papers and book chapters primarily on inhalation of drugs and biologics. He graduated in Chemistry and received PhD in Physical Chemistry from the University of Leeds, England.
Dr. Mauser has over thirty-five years experience as a pulmonary and systems physiologist. During his career he worked for several major pharmaceutical companies including Schering-Plough, Aventis, Novartis, Eisai and Merck. His expertise is in the development of in vivo models of pulmonary disease to assess pharmacological proof of concept in a variety of species including non-human primates. More recently he has been involved in developing and testing novel dry powder inhalation delivery systems. He also spent several years working in clinical research positions that allowed him to develop a strong understanding of the drug development process beyond pre-clinical drug discovery. He has published novel physiological findings and provided numerous lectures and seminars on pulmonary physiology.
Dr. Schremmer is board certified in physician in Internal Medicine, Pulmonary, and Critical Care and a of President, PhenGen Biotech LLC. Dr. He trained in Pulmonary and Critical Care Medicine at the University of Minnesota and was a Postdoctoral Fellow at the National Heart, Lung, and Blood Institute as well as at the University of Pennsylvania. Schremmer holds an M.D. from the University Xavier Bichat in Paris, France and a M.S. in Cardiovascular Physiology from Centre Hospitalo-Universitaire Lariboisière Paris, France. Dr. Schremmer founded PhenGen Biotech, a small biotech company focused on developing a biologics drug discovery platform based on a novel hybrid display technology. He has excellent understanding of unmet medical need in the clinic and passionate about creating innovative therapeutics for improving patient outcomes.
We also consult with industry veterans on various aspects of drug product development.